despit
recent
introduct
mani
improv
immunosuppress
agent
use
transplant
acut
reject
affect
lung
transplant
recipi
within
first
year
transplant
acut
lung
allograft
reject
defin
perivascular
peribronchiolar
mononuclear
inflamm
although
histopatholog
sign
reject
often
resolv
treatment
frequenc
sever
acut
reject
repres
import
risk
factor
subsequ
develop
bronchiol
obliteran
syndrom
bo
condit
progress
airflow
obstruct
limit
surviv
year
lung
transplant
recent
evid
demonstr
peribronchiolar
mononuclear
inflamm
also
known
lymphocyt
bronchiol
even
singl
episod
minim
perivascular
inflamm
significantli
increas
risk
bo
comprehens
review
clinic
present
diagnosi
histopatholog
featur
mechan
acut
cellular
lung
reject
addit
consid
emerg
evid
humor
reject
occur
lung
transplant
character
local
complement
activ
presenc
antibodi
donor
human
leukocyt
antigen
hla
discuss
detail
method
hla
antibodi
detect
well
clinic
relev
mechan
patholog
hallmark
humor
injuri
treatment
option
cellular
reject
includ
highdos
methylprednisolon
antithymocyt
globulin
alemtuzumab
treatment
option
humor
reject
includ
intraven
immunoglobulin
plasmapheresi
rituximab
greater
mechanist
understand
cellular
humor
form
reject
role
pathogenesi
bo
critic
develop
therapi
extend
longterm
surviv
lung
transplant
lung
character
highest
rate
reject
among
commonli
transplant
solid
organ
disappoint
longterm
outcom
despit
modern
immunosuppress
regimen
report
registri
intern
societi
heart
lung
transplant
ishlt
mani
lung
transplant
recipi
treat
acut
allograft
reject
first
year
transplant
lung
recipi
aliv
year
transplant
increas
suscept
lung
injuri
infect
constant
environment
exposur
local
innat
immun
activ
like
contribut
high
rate
reject
multipl
studi
demonstr
acut
vascular
agrad
airway
bgrade
reject
main
risk
factor
bronchiol
obliteran
syndrom
bo
condit
progress
airflow
obstruct
repres
common
caus
death
beyond
first
year
transplant
herein
present
immunolog
basi
acut
lung
allograft
reject
describ
clinic
patholog
featur
acut
cellular
vascular
reject
acut
airway
reject
also
known
lymphocyt
bronchiol
figur
addit
discuss
emerg
understand
import
humor
reject
lung
transplant
includ
use
highli
sensit
solid
phase
technolog
detect
antihuman
leukocyt
antigen
hla
antibodi
present
patient
transplant
develop
de
novo
transplant
highlight
current
strategi
prevent
treatment
cellular
humor
allograft
reject
organ
spong
mammal
evolv
sophist
mechan
permit
recognit
self
nonself
enabl
protect
integr
respond
pathogen
toler
cell
vertebr
host
advanc
interplay
innat
adapt
immun
system
lead
robust
respons
organ
allograft
absenc
immunosuppress
alloimmun
respons
predominantli
driven
cell
recognit
foreign
major
histocompat
complex
mhc
figur
mhc
human
also
refer
human
leukocyt
antigen
hla
repres
protein
complex
encod
set
close
link
gene
mhc
regul
immun
respons
present
antigen
peptid
cell
transplant
allogen
mhc
first
present
directli
recipi
cell
donor
dendrit
cell
graft
direct
pathway
donor
antigenpres
cell
apc
die
destroy
recipi
dendrit
cell
process
present
alloantigen
recipi
cell
indirect
pathway
hla
gene
locat
short
arm
human
chromosom
tradit
divid
two
class
base
histor
differenti
classic
hla
class
gene
includ
b
cw
loci
express
nucleat
cell
classic
hla
class
ii
gene
includ
dr
dq
dp
gene
express
constitut
b
cell
monocyt
dendrit
cell
apc
upregul
varieti
cell
inflammatori
condit
hla
class
molecul
present
primarili
endogen
peptid
cell
hla
class
ii
molecul
present
primarili
exogen
peptid
cell
extraordinari
divers
hla
polymorph
creat
consider
barrier
transplant
donor
organ
quickli
recogn
nonself
basi
hla
differ
recipi
lung
transplant
process
allorecognit
like
augment
local
innat
immun
activ
endogen
tissu
injuri
exogen
infect
well
autoimmun
respons
cryptic
selfepitop
expos
lung
damag
time
transplant
precis
immun
mechan
complex
interact
ultim
lead
stimul
adapt
cellular
immun
lung
reject
remain
fulli
elucid
common
pathway
acut
cellular
reject
involv
recruit
activ
receiv
origin
form
august
accept
final
form
octob
recipi
lymphocyt
predominantli
effector
cell
lung
allograft
result
allograft
injuri
loss
function
consequ
success
outcom
lung
transplant
becom
possibl
widespread
introduct
clinic
practic
calcineurin
inhibitor
cyclosporin
permit
highli
effect
blockad
cell
activ
prolifer
addit
lung
transplant
recipi
appear
mount
humor
respons
allograft
transplant
evid
suggest
humor
respons
occur
donor
mhc
antigen
although
endotheli
epitheli
antigen
express
lung
may
becom
antibodi
target
well
cell
activ
indirect
present
provid
help
b
cell
memori
antibodi
class
switch
affin
matur
presenc
appropri
cytokin
costimulatori
factor
acut
chronic
humor
reject
recent
well
describ
renal
transplant
final
use
modern
solid
phase
antibodi
detect
techniqu
becom
clear
patient
present
transplant
preform
antihla
antibodi
usual
acquir
prior
pregnanc
transfus
transplant
immun
stimul
prior
infect
autoimmun
might
contribut
develop
antibodi
allomhc
patient
identifi
risk
factor
preexist
antibodi
react
donor
antigen
lead
immedi
graft
loss
hyperacut
reject
acceler
humor
reject
bo
diagnosi
acut
cellular
reject
reli
identif
lymphocyt
perivascular
peribronchiolar
infiltr
lung
tissu
mani
episod
acut
reject
diagnos
asymptomat
patient
undergo
surveil
biopsi
symptomat
acut
reject
present
dyspnea
cough
sputum
product
subtl
sign
includ
fever
hypoxia
adventiti
sound
lung
auscult
highergrad
reject
appear
caus
sever
symptom
lead
acut
respiratori
distress
nonspecif
natur
symptom
emphasi
place
object
data
mainli
pulmonari
function
test
identifi
patient
risk
reject
spirometri
found
sensit
greater
detect
infect
reject
grade
higher
differenti
two
use
spirometri
diminish
singl
lung
transplant
recipi
contralater
nativ
lung
dysfunct
confound
pulmonari
function
test
result
pulmonari
function
test
therefor
use
adjunct
clinic
evalu
standalon
definit
diagnost
modal
acut
lung
reject
radiograph
imag
lung
transplant
patient
use
identifi
specif
caus
symptom
decreas
pulmonari
function
focal
infect
neoplasm
find
groundglass
opac
septal
thicken
volum
loss
pleural
effus
highresolut
chest
comput
tomographi
ct
scan
suggest
acut
reject
although
earli
small
studi
attempt
demonstr
use
chest
xray
chest
ct
scan
diagnosi
reject
recent
data
show
low
sensit
acut
reject
low
discriminatori
valu
reject
process
despit
common
clinic
impress
lymphocyt
pleural
effus
hallmark
acut
reject
publish
data
inconclus
fact
lymphocyt
effus
document
absenc
reject
make
difficult
ascertain
whether
mostli
repres
sequela
figur
structur
major
histocompat
complex
mhc
molecul
mhc
class
molecul
compos
heavi
chain
light
chain
chain
compos
three
extracellular
domain
transmembranespan
domain
small
cytoplasm
domain
domain
togeth
form
peptidebind
groov
present
peptid
cell
mhc
class
ii
molecul
heterodim
b
chain
chain
two
extracellular
domain
transmembran
domain
cytoplasm
domain
domain
togeth
form
peptidebind
groov
present
peptid
cell
reject
simpli
physiolog
respons
lung
transplant
summari
light
nonspecif
clinic
symptom
poor
specif
pulmonari
function
test
radiograph
studi
discourag
diagnosi
empir
treatment
reject
base
sole
clinic
sign
symptom
consist
ishlt
definit
requir
histopatholog
analysi
lung
tissu
diagnos
grade
acut
lung
reject
bronchoscopi
bronchoscopi
transbronchi
biopsi
import
modal
diagnosi
acut
allograft
reject
consid
lung
transplant
recipi
allograft
dysfunct
bronchoscopi
allow
acut
reject
distinguish
potenti
etiolog
allograft
dysfunct
airway
stenosi
infect
routin
includ
bronchoalveolar
lavag
bal
cultur
transbronchi
biopsi
histopatholog
analysi
transbronchi
biopsi
perform
lower
lobe
practic
seem
reason
light
data
show
differ
lung
lobe
similar
reject
grade
reject
present
grade
usual
wors
lower
lobe
compar
upper
lobe
lung
reject
studi
group
lrsg
recommend
five
piec
wellexpand
alveol
lung
parenchyma
provid
adequ
sensit
diagnos
reject
advers
event
report
bronchoscopi
lung
transplant
recipi
low
includ
transient
hypoxemia
bleed
ml
pneumothorax
arrhythmia
ventil
support
bronchoscopi
set
report
mortal
low
procedur
risk
bronchoscopi
critic
role
diagnosi
reject
patient
popul
bronchoscop
diagnosi
prefer
empir
treatment
reject
circumst
addit
bronchoscopi
also
perform
surveil
purpos
diagnos
reject
asymptomat
lung
transplant
recipi
rational
surveil
biopsi
includ
occurr
clinic
silent
acut
reject
inadequ
surrog
marker
acut
reject
rel
low
risk
bronchoscopi
procedur
grade
higher
acut
reject
found
rel
high
percentag
asymptomat
patient
rang
yield
acut
reject
report
studi
surveil
transbronchi
biopsi
greater
clinic
indic
bronchoscopi
followup
bronchoscopi
furthermor
acut
reject
seen
even
patient
low
rate
earli
reject
year
transplant
question
import
surveil
bronchoscopi
singlecent
retrospect
studi
suggest
outcom
patient
underw
clinic
indic
bronchoscopi
compar
ishlt
data
howev
random
clinic
trial
ever
compar
differ
posttranspl
monitor
strategi
survey
lung
transplant
center
publish
demonstr
center
perform
schedul
bronchoscopi
addit
clinic
indic
postreject
followup
bronchoscopi
common
schedul
consist
bronchoscopi
month
month
month
annual
basi
regardless
whether
bronchoscopi
perform
clinic
indic
surveil
purpos
incid
acut
reject
highest
within
first
year
transplant
high
clinic
suspicion
acut
reject
maintain
time
period
altern
diagnost
method
acut
lung
reject
attempt
reduc
risk
surveil
bronchoscopi
mani
studi
focus
surrog
acut
lung
reject
particular
focu
direct
identifi
acut
reject
biomark
bronchoalveolar
lavag
bal
mani
posit
studi
small
replic
nevertheless
sever
theme
stand
research
arena
multipl
studi
consid
bal
cellular
composit
relat
reject
infect
earli
month
transplant
increas
leukocytosi
bal
compar
nontranspl
patient
high
number
neutrophil
lymphocyt
acut
reject
associ
elev
cell
activ
cell
trend
toward
increas
nk
cell
increas
b
cell
decreas
nk
cell
bal
nevertheless
studi
proven
bal
cellular
composit
adequ
sensit
specif
discrimin
reject
infect
small
studi
found
correl
acut
reject
elev
interferong
bal
recent
advanc
genom
offer
potenti
specif
mean
diagnos
reject
lung
transplant
pilot
studi
gene
express
bal
lung
transplant
recipi
found
gene
express
signatur
relat
tlymphocyt
function
cytotox
activ
neutrophil
degranul
correl
acut
reject
addit
studi
need
valid
find
establish
whether
bal
microarray
determin
acut
reject
signatur
cost
effect
provid
inform
supplement
replac
biopsi
result
greater
interest
analysi
bal
would
noninvas
mean
diagnos
acut
reject
without
bronchoscopi
exampl
recent
publish
studi
heart
transplant
describ
use
peripher
blood
gene
express
profil
identifi
futur
risk
cardiac
allograft
reject
methodolog
appear
use
predict
persist
neg
biopsi
patient
prior
neg
biopsi
similar
studi
underway
lung
transplant
known
lung
allograft
reject
gene
express
observ
largo
studi
preliminari
data
almost
patient
similarli
cargo
result
show
differenti
gene
express
lymphocyt
prime
neutrophil
homeostasi
pathway
versu
acut
lung
reject
addit
data
valid
may
bring
peripher
blood
test
acut
reject
gene
express
signatur
could
reduc
frequenc
invas
diagnost
procedur
futur
although
effect
serum
biomark
current
use
clinic
lung
transplant
potenti
util
illustr
recent
studi
mark
serum
elev
hepatocyt
growth
factor
hgf
lung
transplant
recipi
associ
acut
reject
smaller
elev
hgf
also
occur
lung
infect
addit
studi
need
valid
specif
sensit
hgf
acut
reject
addit
recent
year
cylex
immun
cell
function
assay
immuknow
cylex
inc
columbia
md
examin
potenti
peripher
blood
surrog
reject
infect
approv
us
food
drug
administr
measur
global
immun
function
solid
organ
transplant
recipi
assay
measur
vitro
product
adenosin
triphosph
atp
patient
cell
respons
stimul
phytohemagglutininl
pha
sever
studi
kidney
liver
heart
small
bowel
allograft
recipi
demonstr
low
atp
level
ngml
correl
infect
high
level
ngml
associ
reject
data
lung
transplant
scarc
promis
date
recent
studi
show
lung
transplant
recipi
activ
infect
like
low
atp
level
compar
stabl
lung
transplant
recipi
mean
versu
ngml
sensit
infect
atp
valu
less
studi
specif
addit
util
atp
measur
assess
two
recipi
patient
sampl
reject
anoth
studi
publish
abstract
form
demonstr
poor
correl
histolog
proven
reject
immuknow
assay
allograft
reject
episod
occur
set
low
moder
atp
level
base
preliminari
result
immuknow
assay
seem
potenti
differenti
infect
reject
lung
transplant
recipi
data
becom
avail
use
clinic
patient
popul
exhal
nitric
oxid
also
attract
marker
lung
injuri
correl
lymphocyt
bronchiol
acut
reject
furthermor
studi
inert
ga
singl
breath
washout
slope
alveolar
plateau
helium
sensit
acut
reject
summari
surrog
marker
suffici
valid
mean
reproduc
identifi
patient
acut
reject
none
supplant
direct
histopatholog
examin
lung
tissu
although
remain
area
intens
research
mani
challeng
exist
develop
noninvas
biomark
reliabl
identifi
acut
reject
includ
probabl
heterogen
reject
phenotyp
lack
interobserv
agreement
histolog
gold
standard
upon
valid
biomark
would
establish
describ
next
section
acut
lung
reject
defin
perivascular
mononuclear
cellular
infiltr
histolog
analysi
lung
allograft
tissu
commonli
diagnosi
establish
base
transbronchi
biopsi
obtain
bronchoscopi
lung
reject
studi
group
lrsg
workshop
organ
ishlt
creat
revis
work
formul
grade
acut
allograft
reject
recent
revis
publish
detail
document
describ
histolog
appear
acut
lung
allograft
reject
outlin
grade
rule
acut
cellular
reject
agrad
airway
inflamm
bgrade
chronic
airway
reject
bronchiol
obliteran
cgrade
chronic
vascular
reject
acceler
graft
vascular
sclerosi
dgrade
grade
scheme
key
featur
summar
tabl
illustr
imag
shown
figur
b
acut
reject
grade
discuss
extens
articl
histopatholog
chronic
reject
discuss
elsewher
issu
see
page
agrad
acut
cellular
reject
lung
allograft
perivascular
mononuclear
infiltr
without
interstiti
mononuclear
cell
thought
repres
typic
acut
lung
allograft
reject
increas
thick
mononuclear
cell
cuff
around
vessel
increas
mononuclear
invas
interstiti
alveolar
space
determin
agrad
tabl
figur
major
mononuclear
cell
cell
although
studi
describ
increas
popul
b
cell
eosinophil
studi
evalu
interand
intraread
reliabl
grade
scheme
two
studi
found
rel
good
interread
agreement
grade
kappa
could
replic
anoth
studi
kappa
spite
dichotom
agrad
versu
intraread
agreement
acut
reject
found
good
infect
complic
diagnosi
viral
infect
particular
caus
mononuclear
inflamm
addit
alveolar
damag
macrophag
fibrin
accumul
found
present
transbronchi
biopsi
first
month
transplant
increas
interread
pathologist
discord
gener
lrsg
recommend
grade
reject
exclus
infect
bgrade
airway
inflamm
mononuclear
airway
inflamm
figur
recogn
sinc
earli
year
lung
transplant
howev
establish
reliabl
relev
grade
scheme
problemat
sever
reason
mani
transbronchi
biopsi
contain
minim
airway
tissu
airway
biopsi
suscept
tangenti
cut
artifact
airway
inflamm
often
accompani
infect
prior
revis
patholog
work
formul
gener
lrsg
initi
recommend
call
airway
inflamm
present
absent
subsequ
expand
grade
grade
current
use
agrad
howev
interread
reliabl
grade
airway
inflamm
bgrade
found
low
kappa
approxim
reason
lrsg
simplifi
bgrade
four
possibl
grade
airway
inflamm
lowgrad
small
airway
inflamm
r
stand
revis
confus
prior
grade
scheme
highgrad
small
airway
inflamm
bx
ungrad
airway
inflamm
tabl
nomenclatur
use
grade
noncartillagin
small
airway
rigor
exclus
infect
multipl
studi
demonstr
acut
reject
major
risk
factor
develop
chronic
airflow
obstruct
singl
episod
acut
reject
well
increas
frequenc
sever
acut
reject
increas
risk
bo
exampl
singl
reject
found
increas
hazard
ratio
hr
develop
bo
p
recurr
reject
increas
hr
p
late
reject
p
howev
lack
prospect
valid
data
prevent
direct
clinic
applic
number
area
controversi
signific
minim
acut
reject
singl
solitari
perivascular
infiltr
earli
year
lung
transplant
reject
usual
discount
treat
studi
found
minim
acut
reject
grade
increas
risk
highergrad
subsequ
reject
grade
find
solitari
perivascular
monocyt
infiltr
follow
worsen
acut
reject
four
untreat
patient
one
studi
treatment
solitari
infiltr
nine
patient
result
improv
reject
score
furthermor
base
multipl
studi
grade
b
lymphocyt
bronchiol
also
known
import
risk
factor
bo
rel
risk
bo
stage
ci
p
death
independ
acut
vascular
reject
larg
airway
inflamm
determin
endobronchi
biopsi
definit
exclud
bgrade
acut
airway
reject
although
larg
airway
inflamm
repres
infecti
tracheobronch
studi
endobronchi
biopsi
demonstr
presenc
noninfecti
cell
rich
inflamm
distinct
inflamm
seen
transbronchi
biopsi
bal
addit
gene
express
found
discord
endobronchi
biopsi
cell
transbronchi
biopsi
tissu
suggest
agrad
reject
process
differ
larg
airway
inflamm
thu
although
lymphocyt
inflamm
frequent
seen
endobronchi
biopsi
clinic
prognost
signific
remain
unclear
demonstr
link
lymphocyt
bronchiti
seen
endobronchi
biopsi
lymphocyt
bronchiol
bronchiti
seen
transbronchi
biopsi
role
atyp
cellular
composit
acut
reject
well
understood
eosinophil
accompani
acut
lung
reject
recogn
revis
lrsg
acut
reject
definit
tabl
presenc
eosinophil
found
portend
poor
prognosi
risk
factor
bo
small
singlecent
studi
high
proport
b
cell
shown
accompani
steroidresist
reject
lung
transplant
patient
mechan
b
cell
contribut
refractori
reject
entir
clear
although
might
reflect
ongo
humor
reject
perhap
explain
diminish
respons
standard
immunosuppress
mast
cell
identifi
acut
reject
biopsi
increas
agrad
role
elucid
addit
immunohistochem
analysi
mononuclear
cell
particip
acut
reject
anoth
import
area
futur
research
despit
larg
number
studi
address
risk
factor
bo
studi
focus
specif
factor
predict
develop
acut
reject
hla
mismatch
gener
thought
intens
host
alloimmun
respons
relat
recipi
recognit
differ
donor
hla
antigen
process
drive
acut
lung
allograft
reject
consist
idea
sever
studi
shown
increas
degre
hla
mismatch
increas
risk
acut
reject
howev
effect
consist
across
hla
loci
studi
mismatch
hladr
hlab
hlaa
loci
well
combin
three
loci
appear
import
howev
singlecent
studi
simpli
enough
patient
power
fulli
assess
clinic
signific
hla
match
sinc
singlecent
studi
rel
patient
high
degre
match
similar
lack
replic
seen
evalu
hla
mismatch
risk
factor
bo
although
sever
singlecent
studi
shown
increas
hla
mismatch
predict
bo
registri
analysi
lung
transplant
recipi
contradict
data
addit
ishlt
registri
found
correl
hla
match
surviv
thu
hla
mismatch
donor
recipi
like
contribut
immunolog
basi
acut
reject
difficult
discern
exist
studi
mismatch
particular
locu
differ
degre
mismatch
significantli
alter
overal
risk
acut
reject
immunosuppress
despit
introduct
new
immunosuppress
mainten
regimen
lung
transplant
recipi
agent
associ
clear
reduct
acut
reject
rate
current
regimen
commonli
employ
calcineurin
inhibitor
corticosteroid
mycophenol
mofetil
mmf
azathioprin
third
agent
sever
studi
suggest
may
lower
incid
acut
reject
tacrolimu
oppos
cyclosporin
selfreport
ishlt
registri
data
also
support
idea
decreas
acut
reject
episod
tacrolimu
compar
cyclosporin
differ
seen
mmf
azathioprin
surprisingli
studi
directli
examin
link
serum
level
immunosuppress
acut
reject
high
level
immunosuppress
measur
indirectli
posit
blood
epsteinbarr
viru
ebv
pcr
found
correl
lower
incid
acut
reject
furthermor
lung
transplant
recipi
develop
one
episod
earli
highgrad
acut
reject
appear
like
develop
addit
acut
reject
episod
within
first
year
lung
transplant
suggest
patient
prior
reject
treat
aggress
immunosuppress
regimen
dose
infect
solid
organ
transplant
viral
infect
long
thought
modul
immun
system
heighten
alloreact
inde
high
incid
acut
reject
found
lung
transplant
recipi
communityacquir
respiratori
tract
infect
human
influenza
viru
respiratori
syncyti
viru
rsv
rhinoviru
coronaviru
parainfluenza
viru
although
cytomegaloviru
cmv
consid
potenti
risk
factor
bronchiol
obliteran
syndrom
studi
directli
link
cmv
infect
cmv
prophylaxi
strategi
acut
reject
inconsist
one
studi
chlamydia
pneumonia
infect
link
develop
acut
reject
bo
recipi
factor
sever
host
genet
characterist
identifi
risk
factor
acut
lung
reject
genotyp
lead
increas
product
may
protect
acut
reject
multidrugresist
genotyp
appear
predispos
persist
acut
reject
resist
immunosuppress
treatment
also
develop
pursu
hypothesi
genet
variat
innat
pattern
recognit
receptor
modul
develop
acut
reject
lung
transplant
found
reduc
acut
reject
variant
tolllik
receptor
blunt
innat
immun
respons
increas
reject
variant
augment
innat
respons
collect
studi
provid
consider
support
overal
hypothesi
constant
interplay
environ
pulmonari
innat
immun
modul
adapt
alloimmun
lung
transplant
effect
age
acut
reject
appear
bimod
lowest
incid
acut
reject
infanc
age
increas
risk
childhood
compar
adulthood
incid
acut
reject
older
lung
transplant
recipi
age
higher
seem
chang
fact
increas
rate
infect
older
lung
transplant
recipi
thought
contribut
increas
mortal
detect
one
center
argu
reduc
immunosuppress
patient
multiorgan
livinglobar
transplant
presenc
multipl
organ
donor
gener
believ
provid
immunolog
advantag
lead
lower
rate
reject
decreas
reject
shown
graft
kidney
liver
heart
combin
heartkidney
liverkidney
heartlung
transplant
recipi
although
benefit
seem
translat
prolong
graft
recipi
surviv
data
regard
lung
reject
presenc
second
organ
remain
inconclus
one
studi
show
decreas
acut
lung
reject
heartlung
transplant
recipi
studi
disput
find
addit
ishlt
registri
report
similar
rejectionrel
mortal
lung
heartlung
recipi
protect
effect
liver
lungliv
recipi
still
debat
well
due
partli
rariti
transplant
procedur
two
three
publish
small
case
seri
lungliv
recipi
show
low
lung
reject
rate
versu
expect
greater
seen
lungonli
recipi
immun
protect
appar
studi
livinglobar
lung
recipi
incid
acut
reject
appear
significantli
differ
baselin
although
lower
rate
bo
describ
summari
precis
mechan
lead
acut
reject
lung
transplant
uncertain
appear
recipi
respons
allograft
modul
degre
hla
mismatch
donor
recipi
environment
factor
includ
natur
intens
immunosuppress
well
local
allograft
exposur
infect
recent
demonstr
genet
variat
recipi
innat
respons
act
concert
factor
regul
develop
acut
reject
clearli
addit
genet
environment
factor
yet
identifi
like
influenc
complex
host
respons
lung
allotransplant
treatment
acut
lung
allograft
reject
consist
increas
immunosuppress
consensu
grade
higher
requir
treatment
earli
clinic
practic
lung
transplant
debat
whether
treat
grade
isol
bgrade
airway
inflamm
light
recent
evid
grade
reject
lymphocyt
bronchiol
major
risk
factor
bo
treatment
seem
prudent
although
indepth
discuss
immunosuppress
found
elsewher
issu
present
brief
overview
acut
reject
treatment
mainstay
treatment
acut
lung
reject
pulsesteroid
sever
studi
show
success
resolut
improv
acut
reject
highdos
steroid
treatment
data
clearli
guid
dose
puls
steroid
standard
dose
mg
methylprednisolon
intraven
although
center
use
dose
rang
mg
per
day
mg
per
day
durat
treatment
also
vari
typic
includ
least
three
dose
follow
oral
prednison
taper
major
challeng
lung
transplant
treatment
resist
persist
recurr
reject
get
diagnos
followup
transbronchi
biopsi
repeat
cours
corticosteroid
one
option
sever
studi
support
switch
cyclosporin
tacrolimu
treatment
persist
acut
reject
mani
center
use
puls
treatment
polyclon
antithymocyt
globulin
atg
receptor
antagonist
recent
report
demonstr
util
alemtuzumab
monoclon
antibodi
treatment
refractori
acut
reject
small
cohort
patient
previous
fail
treatment
atg
inhal
immunosuppress
appeal
treatment
acut
reject
inhal
corticosteroid
found
role
treatment
acut
lung
reject
inhal
cyclosporin
data
initi
encourag
small
studi
show
resolut
acut
reject
decreas
bal
inflammatori
marker
addit
research
need
justifi
use
inhal
cyclosporin
treatment
acut
reject
especi
given
high
incid
side
effect
inhal
carrier
polyethylen
glycol
therapi
consid
manag
sever
persist
acut
reject
includ
extracorpor
photopheresi
total
lymphoid
irradi
relationship
acut
reject
current
treatment
eventu
occurr
bo
area
consider
interest
mani
studi
acut
reject
identifi
risk
factor
bo
despit
patient
undergo
treatment
corticosteroid
acut
reject
one
hand
possibl
treatment
delay
onset
bo
hand
light
recent
explos
knowledg
regard
import
regulatori
cell
transplant
toler
conceiv
certain
reject
treatment
advers
effect
toler
regulatori
mechan
chang
alloreact
unexpect
way
mechanist
understand
acut
reject
relationship
bo
need
develop
new
innov
mean
improv
outcom
lung
transplant
antibodymedi
allograft
reject
increasingli
recogn
entiti
lung
transplant
earli
observ
base
phenomenon
hyperacut
reject
preexist
donorspecif
antibodi
lead
complement
activ
rapid
graft
loss
advent
improv
crossmatch
transplant
incid
hyperacut
reject
organ
decreas
howev
acut
chronic
antibodymedi
lung
reject
emerg
controversi
subject
develop
improv
antibodi
detect
techniqu
allograftspecif
antibodi
implic
acut
chronic
kidney
well
heart
reject
recent
data
expand
concept
lung
transplant
section
discuss
emerg
issu
humor
lung
reject
includ
humor
sensit
lung
transplant
well
patholog
featur
humor
reject
occur
without
presenc
detect
antibodi
technolog
use
hla
antibodi
screen
identif
includ
complementdepend
cytotox
cdc
solid
phase
technolog
elisa
flow
cytometri
luminex
bead
array
assay
complement
depend
cytotox
cdc
methodolog
cdc
assay
use
hla
serolog
type
antibodi
screen
identif
direct
crossmatch
assay
principl
specif
reactiv
serum
antibodi
cell
surfac
antigen
activ
complement
caus
cell
death
dead
cell
subsequ
identifi
microscop
use
vital
dye
cell
stain
hla
serolog
type
use
cdc
technolog
panel
alloantisera
andor
monoclon
antibodi
known
specif
use
determin
type
hla
antigen
donor
cell
surfac
serolog
hla
type
error
prone
due
lack
specif
antibodi
crossreact
sera
solid
organ
transplant
hla
laboratori
current
perform
hla
type
use
sequencespecif
primer
revers
sequencespecif
oligonucleotid
probe
precis
dnabas
detect
realtim
prospect
crossmatch
use
cdc
assay
consist
incub
actual
recipi
serum
actual
donor
leukocyt
identifi
antibodi
bind
cell
death
lung
transplant
due
short
ischemia
time
allow
organ
harvest
transplant
imposs
case
perform
prospect
crossmatch
determin
compat
donor
potenti
recipi
therefor
store
panel
lymphocyt
known
hla
type
use
set
panel
reactiv
antibodi
pra
percentag
lymphocyt
given
panel
recogn
patient
antihla
antibodi
pra
percentag
specif
determin
recipi
time
evalu
compar
hla
type
potenti
donor
time
organ
harvest
howev
due
express
multipl
hla
antigen
cell
difficult
definit
determin
fine
antibodi
specif
method
lead
overal
low
sensit
specif
cdc
detect
system
solid
phase
technolog
antibodi
screen
identif
technolog
significantli
sensit
specif
cdcbase
assay
common
featur
use
solid
matrix
coat
purifi
hla
antigen
obtain
either
cell
line
recombin
technolog
routin
use
solid
phase
technolog
includ
elisa
flow
cytometri
luminex
detect
complementfix
antibodi
noncomplementfix
antibodi
elisa
least
sensit
method
solid
phase
methodolog
use
microtiterpl
surfac
well
precoat
purifi
hla
antigen
incub
patient
serum
secondari
antibodi
chromogen
reaction
visual
specif
antibodyantigen
bind
measur
indirect
immunofluoresc
flow
cytometri
luminex
detect
hla
antibodi
bind
microparticl
coat
purifi
hla
antigen
recombin
singl
antigen
antibodi
screen
flow
cytometri
also
refer
flow
pra
figur
use
panel
popul
bead
coat
hla
antigen
extract
individu
donor
patient
pra
determin
posit
high
actual
hla
specif
recipi
antihla
antibodi
need
determin
flow
cytometr
singl
antigen
bead
assay
allow
accur
identif
specif
hla
antibodi
use
bead
coat
recombin
hla
singl
antigen
figur
recent
develop
solid
phase
methodolog
singl
antigen
detect
luminex
singl
antigen
bead
array
assay
simultan
detect
maximum
differ
color
bead
suspens
differ
hla
antigen
bound
color
bead
provid
even
better
coverag
divers
hla
antigen
antibodi
may
still
present
level
detect
sensit
methodolog
andor
antigen
repres
screen
reagent
howev
believ
antibodi
remain
undetect
current
method
mostli
weak
antibodi
may
clinic
relev
nevertheless
definit
compat
test
remain
realtim
crossmatch
recipi
serum
potenti
donor
cell
flow
crossmatch
wherebi
actual
donor
cell
incub
recipi
serum
bound
antibodi
tag
secondari
fluoresc
antiigg
antibodi
proven
time
sensit
cdc
crossmatch
one
major
goal
donor
select
avoid
hla
antigen
potenti
recipi
preform
antibodi
lung
transplant
recipi
presensit
hla
antigen
recent
develop
sensit
specif
solid
phase
flow
cytometri
luminexbas
methodolog
allow
accur
detect
antibodi
specif
sensit
recipi
technolog
identifi
unaccept
donor
antigen
avoid
time
transplant
donor
becom
avail
inform
donor
hla
antigen
recipi
antibodi
compar
constitut
virtual
crossmatch
allow
realtim
prospect
crossmatch
waiv
other
demonstr
virtual
crossmatch
approach
significantli
shorten
wait
time
presensit
recipi
correl
highli
crossmatch
result
perform
time
transplant
addit
patient
undergo
retransplant
evalu
care
screen
presensit
even
though
unaccept
antigen
avoid
virtual
crossmatch
patient
posit
pretranspl
pra
higher
risk
posttranspl
complic
posttranspl
pra
stay
stabl
increas
via
gener
either
donorspecif
nondonorspecif
antihla
antibodi
similarli
patient
neg
pra
screen
test
transplant
develop
de
novo
nondonorspecif
donorspecif
antihla
antibodi
transplant
use
modern
sensit
antibodi
detect
techniqu
recent
studi
consist
demonstr
increas
incid
acut
reject
threefold
increas
one
studi
persist
reject
increas
bo
hr
ci
p
wors
overal
surviv
median
yr
versu
patient
antihla
antibodi
effect
appar
pretranspl
hla
sensit
develop
de
novo
antihla
donorspecif
antibodi
transplant
import
donor
specif
target
antigen
humor
reject
well
understood
risk
poor
outcom
may
heighten
set
donorspecif
antibodi
posit
retrospect
crossmatch
howev
patient
posit
pra
neg
crossmatch
without
specif
mismatch
donor
hla
antigen
also
found
increas
risk
poor
outcom
one
hand
nondonorspecif
antibodi
present
might
cross
react
donor
hla
antibodi
specif
donor
hla
might
rapidli
absorb
lung
allograft
detect
sera
altern
nonhla
antibodi
could
contribut
graft
injuri
exampl
de
novo
autoimmun
lung
transplant
type
v
collagen
tubulin
express
airway
epitheli
cell
shown
predispos
bo
anoth
studi
demonstr
presenc
antiendotheli
antibodi
direct
donor
antigen
absenc
antihla
antibodi
remain
unclear
exactli
often
posttranspl
pra
measur
extent
humor
reject
occur
among
lung
transplant
recipi
addit
research
need
precis
defin
signific
antibodi
donor
hla
third
parti
hla
selfantigen
lung
transplant
mechan
antibodi
promot
lung
allograft
injuri
remain
poorli
understood
antibodi
bind
allomhc
endotheli
epitheli
target
lung
could
lead
activ
complement
cascad
complement
deposit
lead
endotheli
cell
injuri
product
proinflammatori
molecul
recruit
inflammatori
cell
complementindepend
antibodymedi
mechan
also
induc
endotheli
cell
activ
without
cell
injuri
lead
increas
gene
express
subsequ
prolifer
demonstr
vitro
studi
antihla
antibodi
caus
prolifer
airway
epitheli
cell
well
produc
fibroblaststimul
growth
factor
potenti
contribut
gener
oblit
airway
lesion
hyperacut
reject
lung
transplant
rare
report
use
crossmatch
care
avoid
unaccept
donor
antigen
characterist
patholog
appear
hyperacut
lung
reject
includ
small
vessel
vascul
necrosi
intraalveolar
hemorrhag
diffus
alveolar
damag
common
identif
platelet
fibrin
thrombi
capillari
congest
neutrophil
macrophag
well
antibodi
deposit
endotheli
surfac
vascular
wall
alveolar
space
septa
earli
report
pulmonari
capillar
suggest
separ
form
atyp
reject
presum
due
humor
reject
poorli
respons
steroid
respons
plasmapheresi
recent
studi
attempt
evalu
immunoglobulin
complement
deposit
subendotheli
space
septal
capillari
deposit
immunoglobulin
complement
product
figur
describ
associ
antihla
antibodi
well
allograft
dysfunct
bo
concept
specif
histopatholog
syndrom
associ
humor
reject
remain
controversi
recent
studi
question
relat
complement
immunoglobulin
stain
allograft
reject
other
demonstr
stain
occur
lung
transplant
patient
nonalloimmun
lung
injuri
infect
pgd
evid
antihla
antibodi
differ
stain
techniqu
differ
laboratori
may
explain
inconsist
publish
data
lrsg
report
work
formul
diagnosi
lung
reject
remain
cautiou
discuss
patholog
appear
humor
reject
consensu
capillari
injuri
detect
lung
allograft
biopsi
although
nonspecif
find
find
small
vessel
intim
endotheli
along
immunohistochem
stain
complement
rais
suspicion
humor
reject
although
patholog
find
report
without
evid
antihla
antibodi
visa
versa
presenc
one
patient
antihla
antibodi
patholog
find
suspici
humor
reject
seen
strong
evid
humor
reject
plasmapheresi
mainstay
antibodi
remov
circul
shown
lead
clinic
improv
solid
organ
transplant
humor
reject
well
lung
transplant
recipi
pulmonari
capillar
unrespons
steroid
howev
usual
reserv
sever
case
suspect
humor
reject
given
side
effect
difficulti
administr
intraven
immunoglobulin
ivig
one
common
therapi
use
decreas
antibodymedi
immun
ivig
caus
b
cell
apoptosi
reduc
b
cell
number
downregul
sever
b
cell
surfac
antigen
also
block
bind
donorreact
antibodi
may
inhibit
complement
activ
rel
low
side
effect
profil
peritranspl
use
ivig
plasmapheresi
institut
presensit
patient
led
elimin
antibodi
class
antihla
antibodi
class
ii
antihla
antibodi
stronger
improv
pulmonari
function
decreas
acut
reject
episod
greater
freedom
bo
treat
versu
untreat
yr
kaplanmeir
estim
compar
presensit
patient
get
desensit
therapi
rituximab
monoclon
antibodi
caus
b
cell
deplet
proven
effect
treatment
presensit
renal
transplant
recipi
conjunct
ivig
despit
new
highli
sensit
measur
screen
antihla
antibodi
evid
antibodi
detriment
allograft
optim
monitor
treatment
paramet
humor
reject
transplant
remain
uncertain
studi
need
determin
whether
ivig
plasmapheresi
rituximab
alter
risk
chronic
allograft
dysfunct
sensit
patient
sinc
first
success
human
lung
transplant
acut
reject
defin
perivascular
peribronchiolar
mononuclear
inflamm
recogn
occur
major
patient
reject
thought
occur
result
alloreact
lymphocyt
respond
directli
indirectli
donor
antigen
recent
year
howev
much
complex
pictur
lung
transplant
reject
emerg
addit
hla
divers
genet
variat
innat
immun
pattern
recognit
receptor
also
influenc
risk
posttranspl
reject
furthermor
humor
reject
occur
character
presenc
antibodi
donor
hla
histopatholog
evid
local
pulmonari
complement
activ
final
environment
stimuli
pulmonari
infect
interact
directli
lung
allograft
contribut
develop
reject
thu
lung
allograft
reject
appear
share
mani
featur
solid
organ
transplant
clear
factor
specif
lung
constant
environment
interact
also
contribut
high
preval
lung
allograft
reject
greater
understand
heterogen
lung
reject
critic
develop
therapi
target
precis
biolog
mechan
reject
ultim
improv
longterm
lung
transplant
outcom
